Flutemetamol (18F)
![]()  | |
| Systematic (IUPAC) name | |
|---|---|
| 
 2-[3-(18F)Fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol  | |
| Clinical data | |
| Trade names | Vizamyl | 
| AHFS/Drugs.com | Micromedex Detailed Consumer Information | 
| Pregnancy category  | 
  | 
| Legal status | 
  | 
| Routes of administration  | Intravenous | 
| Identifiers | |
| ATC code | V09AX04 | 
| PubChem | CID 15950376 | 
| ChemSpider | 13092196 | 
| UNII | 0F3M7032P5 | 
| ChEBI | CHEBI:76611 | 
| Chemical data | |
| Formula | C14H1118FN2OS | 
| Molar mass | 273.316 g/mol | 
  | |
  | |
Flutemetamol (18F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.[1]
Mechanism of action
After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).[1]
References
This article is issued from Wikipedia - version of the Sunday, September 21, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
.svg.png)